In today’s Pharmaceutical Executive Daily, Vinay Prasad exits the FDA’s Center for Biologics Evaluation and Research for the ...

The second exit in under a year follows controversy around CRLs for Replimune and Capricor, including criticism that mid- and ...

In a conversation with Pharmaceutical Executive Ron Lanton, Senior Partner & Global Strategist, Lanton, Lanton & Sosa Law ...

David Rosner, principal and global life sciences customer engagement leader at Deloitte, spoke with Pharmaceutical Executive ...

Conversational AI is pushing engagers to prioritize clear, explainable guidance as patients and clinicians delegate understanding to chatbots. OpenAI’s announcement of ChatGPT Health and Anthropic’s ...

After weeks of legal drama, Ozempic is coming Hims & Hers, a telehealth company. Novo Nordisk came to an agreement with the company to offer various doses of the GLP-1 medication for DTC customers. 1 ...

GSK will receive $300 million upfront from Alfasigma for linerixibat, plus $100 million upon anticipated FDA approval and additional regulatory and sales-based milestones with tiered double-digit ...

Based on the clinical trial findings, Ipsen is withdrawing Tazverik across all indications, including both follicular lymphoma and epithelioid sarcoma, and is discontinuing all active tazemetostat ...

Employer Connect aggregates diverse administrators, from basic benefits management to comprehensive obesity programs with wraparound services, enabling employers to tailor coverage models to workforce ...

While regulatory alignment remains essential, operational urgency driving companies to AI adoption is equally profound. In ...

FDA approved Tecvayli (teclistamab-cqyv), a Johnson & Johnson drug developed for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one of line of ...

Market access strategies are evolving as more biopharma companies commercialize their own therapies, requiring closer ...